KeyBanc Downgrades Tempur-Pedic (TPX); Was Not 'Expecting Anything as Dramatic as Today's Announcement'
Tweet Send to a FriendGet Alerts TPX Hot Sheet
Price: $43.08 +1.51%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade TPX Now!
KeyBanc downgraded shares of Tempur-Pedic (NYSE: TPX) from Buy to Hold in a mid-day research note Wednesday. The firm suspended its prior $85 price target.
The downgrade follows sharply reduced FY12 guidance from Tempu-Pedic this morning. The stock is down a jaw-dropping 47 percent at last check.
KeyBanc said it was "not expecting anything as dramatic as today's announcement."
For an analyst ratings summary and ratings history on Tempur-Pedic click here. For more ratings news on Tempur-Pedic click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The downgrade follows sharply reduced FY12 guidance from Tempu-Pedic this morning. The stock is down a jaw-dropping 47 percent at last check.
KeyBanc said it was "not expecting anything as dramatic as today's announcement."
For an analyst ratings summary and ratings history on Tempur-Pedic click here. For more ratings news on Tempur-Pedic click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Macquarie Downgrades Melco Crown Enter. (MPEL) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
KeyBancLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

